Overview

Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction

Status:
Completed
Trial end date:
2016-06-08
Target enrollment:
Participant gender:
Summary
This study explores the potential cardioprotective properties of danegaptide when administered to patients with ST-Segment elevation myocardial infarction.
Phase:
Phase 2
Details
Lead Sponsor:
Zealand Pharma